Annual Report 2022
Department of Pharmacy
Toshikatsu Kawasaki, Yasuhiko Ichida, Reiko Matsui, Masahito Yonemura, Daisuke Kano, Naoko Kumazawa, Shinya Suzuki, Nobuo Mochizuki, Shinichi Masuda, Kenji Kawasumi, Chihiro Nakada, Misaki Takeno, Takahiro Akita, Ayumi Komuro, Yoshihiro Iwamoto, Sayaka Nakajima, Nobue Sato, Yoshiyuki Sano, Akiko Abe, Shinya Uozumi, Yui Suzuki, Masaki Tanaka, Kanako Mamishin, Takashi Igarashi, Tsuyoshi Uemoto, Wataru Suenaga, Hidetaka Suzuki, Yumiko Seto, Ken Demachi, Kensuke Mayumi, Asumi Kaneko, Kazuki Sugisaki, Maho Nakamura, Junko Tauchi, Kaho Miura, Mashiro Okunaka, Manami Harada, Koki Morishita, Atsushi Kawanobe, Kaede Baba
Introduction
The main objectives of the Department of Pharmacy are: (1) To promote clinical studies to create new evidence-based data; (2) To provide chemotherapy based on the most updated evidence-based data; and (3) To pursue patient-centered pharmaceutical care.
Our resident training program started in 2006. In 2022, seven residents joined our department. Presently, we have a total of 20 residents. In addition, our department accepted nine trainees from other institutions for our oncology pharmacist training programs in 2022. In 2022, we educated three pharmacy students.
The Department of Pharmacy provides various important services: controlling inventory, dispensing medications, and preparing i.v. solutions for chemotherapy, which include the aseptic mixing of antineoplastic agents, collecting and providing drug information, managing therapeutic drug monitoring, checking treatment regimens for each patient’s chemotherapy, and providing pharmaceutical management and counseling.
Our department reviews the drugs taken by patients before and during their hospitalization. For inpatient care, our department assigns pharmacists to provide medication counseling and drug information for healthcare providers and patients, to pursue effective pharmaceutical care. For outpatient care, our department provides a pharmacy outpatient service, in which pharmacists check patients for adverse reactions and doses of antineoplastic agents, particularly for oral anticancer medications. We assess the necessity of supportive care medications and coordinate with physicians. The pharmacy outpatient service also reviews the drugs taken by all patients to assess the optimal time for them to stop their anticoagulants before their surgery or stop taking metformin before examinations with iodinated contrast material. Pharmacists are on duty at the Outpatient Chemotherapy Center as dedicated staff members. The pharmacists provide a Chemotherapy Hotline Service, which is a direct line for our outpatients who have any problems concerning their chemotherapy treatment. In the Outpatient Chemotherapy Center, pharmacists are always available to provide drug information for healthcare providers and patients. We also provide treatment information to the patient's community pharmacy so that we can provide seamless pharmaceutical care. We also manage investigational drugs.
Research Activities
We have presented oral sessions and poster sessions 21 times at national and international academic conferences. Seven scientific papers were accepted for publication.
List of papers published in 2022
Journal
1. Zenda S, Arai Y, Sugawara S, Inaba Y, Hashimoto K, Yamamoto K, Saigusa Y, Kawaguchi T, Shimada S, Yokoyama M, Miyaji T, Okano T, Nakamura N, Kobayashi E, Takagi T, Matsumoto Y, Uchitomi Y, Sone M. Protocol for a confirmatory trial of the effectiveness and safety of palliative arterial embolization for painful bone metastases. BMC cancer, 23:109, 2023
2. Shibutani Y, Suzuki S, Sagara A, Enokida T, Okano S, Fujisawa T, Sato F, Yumoto T, Sano M, Kawasaki T, Tahara M. Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer. Frontiers in oncology, 13:1154771, 2023
3. Shibutani Y, Sato H, Suzuki S, Shinozaki T, Kamata H, Sugisaki K, Kawanobe A, Uozumi S, Kawasaki T, Hayashi R. A Case Series on Pain Accompanying Photoimmunotherapy for Head and Neck Cancer. Healthcare (Basel, Switzerland), 11:924, 2023
4. Baba K, Kawamoto M, Mamishin K, Uematsu M, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakajima H, Funasaka C, Nakao T, Kondoh C, Harano K, Matsubara N, Naito Y, Hosono A, Kawasaki T, Mukohara T. The impact of the COVID-19 pandemic on perioperative chemotherapy for breast cancer. Cancer medicine, 2023
5. Niguma K, Mamishin K, Naito Y, Nomura S, Wakabayashi M, Kusuhara S, Funasaka C, Nakao T, Fukasawa Y, Kondoh C, Harano K, Kogawa T, Matsubara N, Hosono A, Onishi T, Kawasaki T, Mukohara T. Impact of Older Age and Medico-social Factors on the Decision to Offer Adjuvant Chemotherapy to Patients With Breast Cancer. Anticancer research, 42:3743-3751, 2022
6. Suzuki H, Mitsunaga S, Ikeda M, Aoyama T, Yoshizawa K, Yamaguchi M, Suzuki M, Narita M, Kawasaki T, Ochiai A. Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer. Cancer medicine, 11:5001-5012, 2022
7. Irisawa A, Takeno M, Watanabe K, Takahashi H, Mitsunaga S, Ikeda M. Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Scientific reports, 12:15574, 2022
8. Uchida M, Suzuki S, Sugawara H, Suga Y, Nakagawa T, Takase H. Multicentre prospective observational study on community pharmacist interventions to reduce inappropriate medications. The International journal of pharmacy practice, 30:427-433, 2022
9. Okunaka M, Kano D, Uesawa Y. Nuclear Receptor and Stress Response Pathways Associated with Antineoplastic Agent-Induced Diarrhea. International journal of molecular sciences, 23:12407, 2022